• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    HC Wainwright & Co. initiated coverage on Reviva Pharmaceuticals with a new price target

    1/24/22 6:07:15 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RVPH alert in real time by email
    HC Wainwright & Co. initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $10.00
    Get the next $RVPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVPH

    DatePrice TargetRatingAnalyst
    9/20/2023$12.00Buy
    ROTH MKM
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    7/26/2021$10.00Buy
    Maxim Group
    More analyst ratings

    $RVPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Narayan Prabhu

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      2/18/25 4:30:51 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Bhat Laxminarayan

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      2/18/25 4:30:30 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Patel Purav

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      12/12/24 4:35:57 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Reviva Pharmaceuticals with a new price target

      ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      9/20/23 7:22:47 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on Reviva Pharmaceuticals with a new price target

      The Benchmark Company initiated coverage of Reviva Pharmaceuticals with a rating of Speculative Buy and set a new price target of $17.00

      6/8/23 7:41:12 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Reviva Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $10.00

      1/24/22 6:07:15 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      11/14/24 5:16:56 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      11/14/24 4:15:57 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13D/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      8/23/24 4:07:26 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Financials

    Live finance-specific insights

    See more
    • Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

      - Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 - - Statistically significant and clinically meaningful reductions in all major symptom domains and secondary endpoints at week 4 with 50 mg of brilaroxazine vs. placebo - - Generally well-tolerated with a side effect profile comparable to placebo for the 15 and 50 mg doses of brilaroxazine; discontinuation rates for brilaroxazine lower than placebo - - Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 - - Conference call and webcast

      10/30/23 7:30:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

      9/29/23 9:00:00 AM ET
      $AREC
      $RVPH
      $STSS
      Coal Mining
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel

      9/22/23 1:30:00 PM ET
      $ARDS
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reviva to Participate in the Citizens Life Sciences Conference

      CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Citizens Life Sciences Conference, taking place May 7-8, 2025, in New York, NY. Citizens Life Sciences Conference Format: Corporate Update / Fireside ChatDate: Thursday, May 8, 2025Time: 10:30 a.m. ETLocation: New York, NYWebcast Link: Click Here About Reviva Reviva is

      4/29/25 8:00:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

      CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present a late-breaking poster presentation on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting, taking place May 27-30, 2025, in Scottsdale, AZ. Details for the poster

      4/24/25 8:00:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

      – Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – – Full data set from RECOVER OLE expected in Q2 2025 – CUPERTINO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31, 2024

      3/31/25 4:05:15 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

      Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

      12/20/24 7:00:00 AM ET
      $APLT
      $RVPH
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    SEC Filings

    See more
    • SEC Form S-8 filed by Reviva Pharmaceuticals Holdings Inc.

      S-8 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      4/3/25 7:55:15 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Reviva Pharmaceuticals Holdings Inc.

      NT 10-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      3/31/25 5:16:54 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      3/31/25 4:12:22 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care